Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021)
Castle Biosciences (CSTL) posted Current Deferred Revenue of $3.0 million for Q3 2021, down 51.45% sequentially from $6.2 million in Q2 2021, and down 64.08% YoY from $8.4 million in Q3 2020.
Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021) Analysis & Trends
Castle Biosciences has reported Current Deferred Revenue for 2 years, with the latest figure at $3.0 million in Q3 2021.
- Quarterly Current Deferred Revenue fell 64.08% year-over-year to $3.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $3.0 million (down 64.08% YoY) and the FY2020 annual result came in at $6.6 million, changed N/A from the prior year.
- Current Deferred Revenue slipped to $3.0 million in Q3 2021 per CSTL's latest filing, from $6.2 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $8.4 million in Q2 2020 and troughed at $3.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn |
| 10 | Castle Biosciences | 1.04 Bn | 773.13 Mn | 79.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 3.00 Mn |
| Jun 30, 2021 | 6.18 Mn |
| Mar 31, 2021 | 8.18 Mn |
| Dec 31, 2020 | 6.62 Mn |
| Sep 30, 2020 | 8.35 Mn |
| Jun 30, 2020 | 8.35 Mn |